In the KEYNOTE-427 trial from advanced non-clear cell RCC the response rate was 35.3% with a CPS ≥1 as opposed to 12.1% in patients with CPS less than 1.47 Combinations of immune checkpoint inhibitors with TKIs such as cabozantinib and axitinib have higher anti-tumor activity and are currently approved for treatment of metastatic clear cell RCC.48,49 Selecting tumors with higher PD-L1 expression such as those with NF2 GA might expand the benefit of these combinations to non-clear cell RCC. Here, CD274 is linked to neoplasm.